CELYAD ONCOLOGY SA |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.32 EUR | -3.03% |
|
-5.74% | -17.95% |
| Apr. 04 | Celyad Oncology SA Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Feb. 09 | Celyad Oncology Seeks Termination of Reporting Obligations to US SEC | MT |
| Sales 2022 | - | Sales 2023 | 102K 109K | Capitalization | 16.16M 17.29M |
|---|---|---|---|---|---|
| Net income 2022 | -40M -42.79M | Net income 2023 | -8M -8.56M | EV / Sales 2022 | - |
| Net cash position 2022 | 12.19M 13.04M | Net cash position 2023 | 5.95M 6.36M | EV / Sales 2023 | 100 x |
| P/E ratio 2022 |
-0.28
x | P/E ratio 2023 |
-1.19
x | Employees | 18 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 92.37% |
More Fundamentals
* Assessed data
More news
Latest transcript on Celyad Oncology SA
More recommendations
More press releases
More news
| 1 day | -3.03% | ||
| 1 week | -5.74% | ||
| Current month | -8.83% | ||
| 1 month | -9.86% | ||
| 3 months | -11.36% | ||
| 6 months | -53.62% | ||
| Current year | -17.95% |
1 week
0.31
0.34
1 month
0.300.38
Current year
0.300.47
1 year
0.301.28
3 years
0.306.02
5 years
0.3018.92
10 years
0.3070.95
| Managers | Title | Age | Since |
|---|---|---|---|
Michel Lussier
FOU | Founder | 67 | 07-07-23 |
David Georges
DFI | Director of Finance/CFO | - | 18-12-31 |
Eytan Breman
CTO | Chief Tech/Sci/R&D Officer | - | 14-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Michel Lussier
FOU | Founder | 67 | 07-07-23 |
Hilde Windels
CHM | Chairman | 59 | 18-05-06 |
Serge Goblet
BRD | Director/Board Member | - | 07-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-24 | 0.32 | -3.03% | 9 263 |
| 24-04-23 | 0.33 | +3.13% | 19,412 |
| 24-04-22 | 0.32 | -5.74% | 7,803 |
| 24-04-19 | 0.3395 | +4.14% | 15,243 |
| 24-04-18 | 0.326 | -2.54% | 2,604 |
Real-time Euronext Bruxelles, April 24, 2024 at 11:35 am EDT
More quotes
Celyad Oncology SA is a biotechnology company focused on the discovery and development of innovative technologies chimeric antigen receptor (CAR) T-cell therapies. The company is focusing on opportunities to fully harness the true potential of its proprietary technology platforms and intellectual property and support the development of next-generation CAR T candidates in solid tumors and hematological malignancies.
Calendar
2024-05-01
- Q1 2024 Earnings Release (Projected)
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -17.95% | 14.63M | |
| +4.09% | 43.43B | |
| +47.81% | 41.69B | |
| +9.45% | 41.31B | |
| -10.92% | 27.14B | |
| +9.32% | 25.28B | |
| -24.87% | 18.47B | |
| +29.70% | 12.59B | |
| +1.28% | 12.33B | |
| +7.78% | 11.03B |
- Stock Market
- Equities
- CYAD Stock
